TriNet Group (TNET) reported third-quarter earnings of $0.65 per share, below the $0.66 consensus and well short of the $0.74 Earnings Whisper number. That works out to a 12.2% miss. Earnings fell 44.4% year over year, and revenue of $1.175 billion declined 4.6%. The headline is weak, but the call told a different story. Management reaffirmed full-year guidance, said it now expects adjusted EPS at the top of the $4.50-$5.10 range, and reported that new sales returned to growth while retention recovered. That is the central tension. The earnings line is shrinking, while the leading indicators of a turnaround are finally moving the right way.

The basis of the comparison needs a note. The $0.65 figure is GAAP diluted EPS, compared with $0.70 a year ago. On the adjusted basis management emphasizes, EPS was $0.94, down from $1.11. Adjusted EBITDA fell 11% to $89 million, and the margin narrowed to 7.6% from 8.2%. The reported 366.4% revenue surprise against a $251.94 million consensus also appears to reflect a narrower revenue definition than TriNet's total revenue, so investors should not read it as a genuine top-line blowout. The real revenue picture is more sobering. Total revenue fell 5% for the third straight quarter with no sign of deceleration in the decline. Professional service revenue dropped 7% to $157 million, and interest income slipped to $13 million from $17 million. Worksite employees fell 11% to roughly 295,000, down sequentially from about 300,000 in Q2.

The quality of the quarter's profit also deserves scrutiny. The insurance cost ratio improved a point to 89%, which is genuine underwriting progress. However, Q3 earnings were helped by non-recurring R&D tax credits that cut the effective tax rate to 19%. Q2 had also benefited from a one-time insurance cost ratio recovery of roughly 50 basis points. Management acknowledged both items create tougher 2027 comparisons. Operating expenses rose about 2% on the Cocoon acquisition and accelerated sales investment. Free cash flow of $53 million was roughly flat with last year and down from $67 million in Q2, though operating cash flow rose 11% to $80 million.

Beneath those numbers, the operating story genuinely improved. New sales ACV grew mid-single digits in Q3 after flat growth in Q2, and management forecast high-single-digit growth for the fall-dominated Q4. Full-year retention is now expected to modestly exceed the historical average of about 80%. That is a meaningful recovery from January's attrition, which ran roughly two points worse than normal. Several other drivers support the story:

• The broker channel was a strong contributor to new sales.
• Sales consultants are up more than 10%, with 110-plus Ascend trainees building 2027 capacity.
• AI now resolves about 60% of worksite-employee chats, up from 50% last quarter.
• New Recruit and Spend partnerships broaden the product offering.
• Leverage is back near the 2x target.

Management also suggested that competitors pushing outsized renewal increases could open a client-acquisition window. The guidance mix shows the split. Professional service revenue, adjusted EBITDA margin, the insurance cost ratio, and adjusted EPS are all tracking to the favorable end of their ranges. Total revenue, however, is now heading to the bottom of its $4.75-$4.90 billion range, down from at or slightly below the midpoint last quarter. Bears have legitimate ammunition in the forward risks:

• Pharmacy costs normalized higher in Q3, and GLP-1 and specialty drug trends are expected to reassert.
• Health cost trend remains in the high single digits.
• Clients may cut plan participation or buy down coverage.
• Professional services verticals showed no net hiring amid higher rates.
• The full-year guide implies a Q4 step-up in the insurance cost ratio and a step-down in EPS.

Investors were not positioned for a collapse. Earnings Whispers sentiment moved from modestly negative (-0.10) to modestly positive (+0.08), a real but not dramatic shift. Shares entered the report at $70.41, up 3.0% since the open after the July report and nearly 32% above the 200-day moving average. However, the stock sat 8.1% below the 52-week high of $76.59 set on October 23, after rebounding about 14% from a late-September low. Price and momentum trends remain constructive, while sequential growth is only neutral, consistent with a stock rewarded for its pipeline more than its current growth.

The bottom line is that TriNet's quarter disappointed on the headline and flattered on the tax line, yet it delivered the evidence turnaround skeptics have been waiting for: improving new sales, recovering retention, and earnings guidance tilting high. The test now shifts to whether Q4 selling and January retention can stop the worksite-employee decline before rising healthcare costs and tougher 2027 comparisons squeeze margins.